Website intended for a NZ health professional readership
This article was first published in New Zealand Doctor Rata Aotearoa on 11 September 2024.
Psychiatrist David Codyre reviews the growing evidence for low-dose naltrexone in the treatment of functional syndromes such as fibromyalgia, chronic fatigue and long COVID
Kia ora and welcome to Pharmacy Today Kaitiaki Rongoā O Te Wā
Not a subscriber? Unlock this article by subscribing here.
1. Toljan K, Vrooman B. Low-dose naltrexone (LDN) – review of therapeutic utilization. Med Sci (Basel) 2018;6(4):82.
2. Hatfield E, Phillips K, Swidan S, et al Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. J Am Dent Assoc 2020;151(12):891–902.e1.
3. Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018;16(1):55.
4. O’Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health 2022;24:100485.
Academic pharmacist Nataly Martini discusses the medical management of asthma in adults and adolescents, which has evolved to prioritise early anti-inflammatory treatment. She also explains how to improve patient outcomes by proactively identifying poor asthma control and supporting equitable access to education and treatment
Ever heard these myths from smokers?
